synephrineWhat was measured
Measured, with no finding
387 endpoints
Show what was measuredHide what was measured
duration of medication administration
no effect
Results showed no statistically significant differences across all aroma conditions for either resistive behavior or duration of administration
PMID 12083347 · one of two readings recorded this
resistive behavior and duration of administration
no effect
Also, there were no statistically significant differences based on gender
PMID 12083347 · one of two readings recorded this
resistive behavior during medication administration
no effect
Results showed no statistically significant differences across all aroma conditions for either resistive behavior or duration of administration
PMID 12083347 · one of two readings recorded this
weight loss
no effect, n = 20
identified only 1 eligible randomized placebo controlled trial, which followed 20 patients for 6 weeks, demonstrated no statistically significant benefit for weight loss
PMID 15541270 · one of two readings recorded this
blood pressure
no effect
Blood pressures for the hypertensive individuals did not change significantly in response to the dietary supplement
PMID 21448304 · one of two readings recorded this
dependent variables
no effect
No significant differences were observed for the dependent variables in the female group
PMID 21448304 · one of two readings recorded this
dependent variables
no effect
males did not demonstrate significant differences when the dietary supplement was ingested
PMID 21448304 · one of two readings recorded this
effect sizes of gender and caffeine-consumption subgroup analyses
The effects based on number of subjects per group were all below 0.4, indicating low to moderate influence
PMID 21448304 · one of two readings recorded this
heart rate and blood pressure
no effect
As with the previous analyses, no significant differences were observed for heart rates or blood pressures between the experimental and placebo control groups
PMID 21448304 · one of two readings recorded this
heart rate, blood pressure and metabolic variables
no effect, n = 23
No statistical differences were observed within groups or between groups for any of the measures
PMID 21448304 · one of two readings recorded this
respiratory exchange ratio (RER)
decreases
there was a small but significant change in RER data for the low caffeine users relative to both the placebo control group and the pre-treatment baseline for the low caffeine group
PMID 21448304 · one of two readings recorded this
respiratory exchange ratio (RER)
decreases
After ingestion of dietary supplement the low caffeine users exhibited a decrease in RER from 0.84 ± 0.05 to 0.81 ± 0.04
PMID 21448304 · one of two readings recorded this
resting heart rate, auscultatory blood pressure and respiratory exchange ratio after the supplement versus placebo
no effect, no statistical differences within or between groups for any measure, n = 23
Not recorded as a finding: the intervention held more than the compound
No statistical differences were observed within groups or between groups for any of the measures.
PMID 21448304 · one of two readings recorded this
resting heart rate, systolic and diastolic blood pressure, mean arterial pressure and respiratory exchange ratio after a multi-ingredient capsule
no effect
Not recorded as a finding: the intervention held more than the compound
No statistical differences were observed within groups or between groups for any of the measures.
PMID 21448304 · one of two readings recorded this
baseline diastolic blood pressure
The average baseline blood pressures and resting heart-rates for the study cohort were well within the normal ranges of 121/74 mm Hg and 70 BPM
PMID 21537493 · one of two readings recorded this
baseline-ending change in blood pressure and heart rate, between-group differences
no effect
None of the baseline-ending changes approached statistical significance nor were there any statistically significant differences between any of the five study groups
PMID 21537493 · one of two readings recorded this
baseline resting heart rate
The average baseline blood pressures and resting heart-rates for the study cohort were well within the normal ranges of 121/74 mm Hg and 70 BPM
PMID 21537493 · one of two readings recorded this
baseline systolic blood pressure
The average baseline blood pressures and resting heart-rates for the study cohort were well within the normal ranges of 121/74 mm Hg and 70 BPM
PMID 21537493 · one of two readings recorded this
change in resting metabolic rate (kcal) 75 min after ingestion, MedGem hand-held indirect calorimeter; also seated blood pressure, heart rate and 10-item self-report symptoms
increases, 65 kcals over placebo for 50 mg p-synephrine alone (Group 2), n = 10
Not recorded as a finding: this platform holds no node for the endpoint
As compared to placebo, 50 mg p-synephrine (Advantra Z®) alone (Group 2) more than doubled consumption by 65 kcals over placebo.
PMID 21537493 · one of two readings recorded this
resting metabolic rate by MedGem hand-held indirect calorimeter 75 min after p-synephrine 50 mg (as Advantra Z) alone versus placebo; blood pressure and heart rate were also measured
RMR change 65 kcal greater than placebo, no test against placebo stated for this group
Not recorded as a finding: this platform holds no node for the endpoint
As compared to placebo, 50 mg p-synephrine (Advantra Z®) alone (Group 2) more than doubled consumption by 65 kcals over placebo.
PMID 21537493 · one of two readings recorded this
resting metabolic rate by MedGem hand-held indirect calorimeter (oxygen consumption only), seated, change from baseline in kcal at 75 min after an oral dose; also blood pressure, heart rate and a 10-item self-report symptom scale
increases, 65 kcal greater than placebo (Group 2, 50 mg p-synephrine alone); no significance stated for this contrast
Not recorded as a finding: a node exists but the paper states a different instrument or population
As compared to placebo, 50 mg p-synephrine (Advantra Z®) alone (Group 2) more than doubled consumption by 65 kcals over placebo.
PMID 21537493 · one of two readings recorded this
resting metabolic rate, change from baseline in kcal at 75 min after ingestion, measured seated with the MedGem hand-held indirect calorimeter (oxygen consumption only), p-synephrine 50 mg as Advantra Z alone vs V-8 juice placebo
increases, 65 kcal over placebo for the p-synephrine-alone group; no test statistic stated for that contrast, n = 10
Not recorded as a finding: a node exists but the paper states a different instrument or population
As compared to placebo, 50 mg p-synephrine (Advantra Z®) alone (Group 2) more than doubled consumption by 65 kcals over placebo.
PMID 21537493 · one of two readings recorded this
resting metabolic rate change from baseline
increases, n = 10
As compared to placebo, 50 mg p-synephrine (Advantra Z®) alone (Group 2) more than doubled consumption by 65 kcals over placebo
PMID 21537493 · one of two readings recorded this
resting metabolic rate change from baseline
increases, n = 10
In Group 3, adding 600 mg naringin to the 50 mg p-synephrine further increased calorie consumption more than three-fold to 122 kcals over placebo
PMID 21537493 · one of two readings recorded this
resting metabolic rate change from baseline
increases, n = 10
The addition of 100 mg hesperidin to the p-synephrine plus naringin in Group 4 resulted in a further increase in calorie consumption by 5-fold to 183 kcal over placebo
PMID 21537493 · one of two readings recorded this
resting metabolic rate change from baseline
increases, n = 10
However, in Group 5, when the amount of hesperidin consumed in conjunction with the 50 mg p-synephrine plus 600 mg naringin was increased to 1000 mg, the increase in calorie consumption over placebo was only 79 kcal
PMID 21537493 · one of two readings recorded this
resting metabolic rate change from baseline
increases, p = 0.001, n = 10
a repeated-measures Students' t-test revealed that the changes from baseline in Group 3 and Group 4 were both statistically significant (P=0.001 and 0.030, respectively)
PMID 21537493 · one of two readings recorded this
resting metabolic rate change from baseline
increases, p = 0.03, n = 10
a repeated-measures Students' t-test revealed that the changes from baseline in Group 3 and Group 4 were both statistically significant (P=0.001 and 0.030, respectively)
PMID 21537493 · one of two readings recorded this
resting metabolic rate increase, significance test against placebo
increases, p = 0.039, n = 10
the increases in RMR in Group 4 was significantly greater than placebo (P=0.039)
PMID 21537493 · one of two readings recorded this
systolic and diastolic blood pressure and heart rate change
no effect
At the conclusion of the study (75 min.), no increases in either systolic or diastolic blood pressures or heart rate were observed
PMID 21537493 · one of two readings recorded this
ten self-reported symptom ratings
no effect
As compared to the placebo group, none of the changes in these 10 self-reported symptoms were statistically significant either 45 or 75 min. from baseline
PMID 21537493 · one of two readings recorded this
ten self-reported symptom ratings
no effect
As compared to the placebo group, none of the changes in these 10 self-reported symptoms were statistically significant either 45 or 75 min. from baseline
PMID 21537493 · one of two readings recorded this
Cure-markedly effective cases, cumulative at interim analysis 1
n = 62
1 | 32 | 30 | 20 | 12 | 14 | 16 | 2.45 | 3.83
PMID 21762493 · one of two readings recorded this
Cure-markedly effective cases, cumulative at interim analysis 2
n = 116
2 | 60 | 56 | 38 | 22 | 26 | 30 | 4.89 | 7.16
PMID 21762493 · one of two readings recorded this
Cure-markedly effective cases, cumulative at interim analysis 3
n = 160
3 | 82 | 78 | 55 | 27 | 35 | 43 | 8.89 | 9.82
PMID 21762493 · one of two readings recorded this
Cure-markedly effective rate, odds ratio for IFCA relative to IFCS
increases, n = 160
the median unbiased estimate of the odds ratio (OR) for the benefit of IFCA relative to IFCS was 2.91 with 95%CI: 1.40 to 6.06
PMID 21762493 · one of two readings recorded this
Cure-markedly effective rate (primary outcome), at stopping
increases, p = 0.0036, n = 160
the cure-markedly effective rates were 67% for IFCA group and 45% for IFCS group, the one-sided p-value was 0.0036
PMID 21762493 · one of two readings recorded this
Syndrome integral, after treatment
n = 160
the after-treatment syndrome integral were 5.5 ± 2.1 for IFCA group and 6.3 ± 2.3 for IFCS group
PMID 21762493 · one of two readings recorded this
Syndrome integral, before treatment
no effect, n = 160
Before-treatment syndrome integral | 17.3 ± 4.8 | 17.0 ± 4.3
PMID 21762493 · one of two readings recorded this
Average concentric force across successive sets, time effect
decreases, p = 0.03, n = 12
A significant time effect was observed [P = 0.03] where average concentric force decreased from set 1 through set 6 at various points (data not shown)
PMID 26388707 · one of two readings recorded this
Average power across successive sets, time effect
decreases, p = 0.0001, n = 12
A significant time effect was observed [P < 0.0001] where average power decreased with each successive set
PMID 26388707 · one of two readings recorded this
Average power, mean of 6 sets, S vs CT and P
no effect, n = 12
Although mean power during S was higher than CT and P, this value did not reach statistical significance
PMID 26388707 · one of two readings recorded this
Average power, mean of 6 sets, SCF vs CT and P
increases, p = 0.03, n = 12
The mean power for all 6 sets was significantly higher in SCF compared to CT and P by ~6.2 ± 8.0 % [P = 0.03]
PMID 26388707 · one of two readings recorded this
Average power, mean of 6 sets
increases, n = 12
Mean | 697 ± 108.6 | 697 ± 106.5 | 718.8 ± 124.6 | 743.0 ± 129.3*
PMID 26388707 · one of two readings recorded this
Average power, set 1
n = 12
Set 1 | 827.7 ± 160.8 | 870.4 ± 153.9 | 860.8 ± 155.0 | 875.6 ± 160.4
PMID 26388707 · one of two readings recorded this
Average power, set 2
n = 12
Set 2 | 734.3 ± 127.2a | 756.7 ± 144.3a | 777.5 ± 160.9a | 794.4 ± 152.5a
PMID 26388707 · one of two readings recorded this
Average power, set 3
n = 12
Set 3 | 681.2 ± 126.6ab | 677.1 ± 119.2ab | 703.6 ± 186.4ab | 729.7 ± 150.5ab
PMID 26388707 · one of two readings recorded this
Average power, set 4
n = 12
Set 4 | 653.1 ± 134.1ab | 622.6 ± 133.7abc | 642.8 ± 169.4abc | 682.4 ± 144.6abc
PMID 26388707 · one of two readings recorded this
Average power, set 5
n = 12
Set 5 | 600.9 ± 113.8abcd | 598.2 ± 131.2abc | 622.8 ± 140.2abc | 644.7 ± 153.0abcd
PMID 26388707 · one of two readings recorded this
Average power, set 6
n = 12
Set 6 | 595.1 ± 100.5abcd | 574.4 ± 114.6abcde | 561.4 ± 121.4abcde | 614.8 ± 141.8abcde
PMID 26388707 · one of two readings recorded this
Average velocity across successive sets, time effect
decreases, p = 0.0001, n = 12
A significant time effect was observed [P < 0.0001] where average velocity decreased with each successive set
PMID 26388707 · one of two readings recorded this
Average velocity, mean of 6 sets, S vs CT and P
no effect, n = 12
Although mean velocity during S was higher than CT and P, this value did not reach statistical significance
PMID 26388707 · one of two readings recorded this
Average velocity, mean of 6 sets
increases, n = 12
Mean | 0.38 ± 0.05 | 0.38 ± 0.06 | 0.39 ± 0.07 | 0.40 ± 0.07*
PMID 26388707 · one of two readings recorded this
Average velocity per set, SCF vs CT and P
increases, p = 0.04, n = 12
The mean velocity per set was significantly greater [P = 0.04] in SCF than CT and P by ~6.5 ± 8.0 %
PMID 26388707 · one of two readings recorded this
Average velocity, set 1
n = 12
Set 1 | 0.46 ± 0.06 | 0.49 ± 0.06 | 0.47 ± 0.06 | 0.48 ± 0.05
PMID 26388707 · one of two readings recorded this
Average velocity, set 2
n = 12
Set 2 | 0.41 ± 0.05a | 0.42 ± 0.07a | 0.43 ± 0.07a | 0.44 ± 0.07a
PMID 26388707 · one of two readings recorded this
Average velocity, set 3
n = 12
Set 3 | 0.38 ± 0.06ab | 0.38 ± 0.07ab | 0.38 ± 0.09ab | 0.40 ± 0.07ab
PMID 26388707 · one of two readings recorded this
Average velocity, set 4
n = 12
Set 4 | 0.36 ± 0.06ab | 0.34 ± 0.07abc | 0.35 ± 0.09abc | 0.38 ± 0.08abc
PMID 26388707 · one of two readings recorded this
Average velocity, set 5
n = 12
Set 5 | 0.33 ± 0.06abcd | 0.33 ± 0.08abc | 0.34 ± 0.07abc | 0.35 ± 0.08abcd
PMID 26388707 · one of two readings recorded this
Average velocity, set 6
n = 12
Set 6 | 0.33 ± 0.06abcd | 0.32 ± 0.07abcde | 0.31 ± 0.07abcde | 0.34 ± 0.08abcde
PMID 26388707 · one of two readings recorded this
Blood lactate across sampling times, time effect
increases, p = 0.0001, n = 12
A significant time effect was observed [P < 0.0001] where blood lactate was significantly elevated at T3, T4, and T5 compared to T1 and T2
PMID 26388707 · one of two readings recorded this
Blood lactate, supplement effect
no effect, p = 0.98, n = 12
No significant supplement effects were observed [P = 0.98]
PMID 26388707 · one of two readings recorded this
Body mass during each experimental protocol
no effect, n = 12
Body mass did not significantly differ during each experimental protocol; CT = 82.0 ± 9.2 kg; P = 81.7 ± 9.4 kg; S = 82.0 ± 9.8 kg; and SCF = 81.6 ± 9.4 kg
PMID 26388707 · one of two readings recorded this
Daily dietary energy intake
n = 12
Subjects consumed an average of 2,594.2 ± 568.3 kcals per day
PMID 26388707 · one of two readings recorded this
Mean concentric force of 6 sets
no effect, p = 0.24, n = 12
The mean concentric force across all 6 sets did not significantly differ among conditions (CT = 1875.9 ± 229.6 N; P = 1901.1 ± 210.5 N; S = 1898.1 ± 217.0 N; SCF = 1902.7 ± 222.9 N) [P = 0.24]
PMID 26388707 · one of two readings recorded this
Mean peak power of 6 sets
no effect, p = 0.67, n = 12
No significant differences were observed [P = 0.67] between treatments when examining the mean peak powers of all 6 sets (CT = 1315.2 ± 195.9 W; P = 1289.8 ± 170.6 W; S = 1294.0 ± 174.4 W; SCF = 1329.1 ± 197.2 W)
PMID 26388707 · one of two readings recorded this
Mean peak velocity of 6 sets
no effect, p = 0.84, n = 12
No significant differences were observed [P = 0.84] between treatments when examining the mean peak velocities of all 6 sets (CT = 0.71 ± 0.06 m⋅s−1; P = 0.70 ± 0.10 m⋅s−1; S = 0.70 ± 0.07 m⋅s−1; SCF = 0.72 ± 0.08 m⋅s−1)
PMID 26388707 · one of two readings recorded this
Mean session RPE, treatment effect
no effect, p = 0.18, n = 12
no significant treatments effects were observed for the mean session RPE [P = 0.18]
PMID 26388707 · one of two readings recorded this
Nutritional intake across experimental conditions
no effect, n = 12
Statistical analysis of the 3-day dietary records showed that subject nutritional intake did not vary between the four experimental conditions
PMID 26388707 · one of two readings recorded this
Peak concentric force, mean of 6 sets, treatment effect
no effect, p = 0.21, n = 12
No significant differences were observed [P = 0.21] between treatments when examining the mean peak concentric force of all 6 sets
PMID 26388707 · one of two readings recorded this
Peak concentric force, mean of 6 sets
no effect, n = 12
Mean | 2212.1 ± 258.0 | 2235.0 ± 266.7 | 2248.8 ± 266.9 | 2268.5 ± 277.1
PMID 26388707 · one of two readings recorded this
Peak concentric force, set 1
n = 12
Set 1 | 2256.5 ± 290.3 | 2295.1 ± 281.6 | 2287.8 ± 286.2 | 2328.8 ± 306.5
PMID 26388707 · one of two readings recorded this
Peak concentric force, set 2
n = 12
Set 2 | 2232.6 ± 276.9 | 2262.0 ± 296.4a | 2265.9 ± 283.2 | 2301.0 ± 289.7
PMID 26388707 · one of two readings recorded this
Peak concentric force, set 3
n = 12
Set 3 | 2217.4 ± 249.5 | 2249.4 ± 272.0a | 2252.7 ± 259.0a | 2277.1 ± 283.6ab
PMID 26388707 · one of two readings recorded this
Peak concentric force, set 4
n = 12
Set 4 | 2207.0 ± 254.8a | 2224.5 ± 270.8a | 2251.9 ± 280.7a | 2262.0 ± 287.0ab
PMID 26388707 · one of two readings recorded this
Peak concentric force, set 5
n = 12
Set 5 | 2184.1 ± 258.4ab | 2208.4 ± 251.9abc | 2224.9 ± 267.8ab | 2227.5 ± 268.6abcd
PMID 26388707 · one of two readings recorded this
Peak concentric force, set 6
n = 12
Set 6 | 2175.3 ± 252.9ab | 2170.9 ± 240.4abcde | 2209.7 ± 244.0abc | 2214.3 ± 241.6abcd
PMID 26388707 · one of two readings recorded this
Peak power across successive sets, time effect
decreases, p = 0.0001, n = 12
A significant time effect was observed [P < 0.0001] where peak powers decreased with each successive set (data not shown)
PMID 26388707 · one of two readings recorded this
Peak velocity across successive sets, time effect
decreases, p = 0.0001, n = 12
A significant time effect was observed [P < 0.0001] where peak velocities decreased with each successive set (data not shown)
PMID 26388707 · one of two readings recorded this
Rating of perceived exertion, session mean
n = 12
Mean | 7.23 ± 1.12 | 7.14 ± 1.58 | 6.84 ± 1.49 | 7.06 ± 1.44
PMID 26388707 · one of two readings recorded this
Rating of perceived exertion, set 1
n = 12
Set 1 | 5.36 ± 1.5 | 5.18 ± 1.60 | 5.14 ± 1.27 | 5.41 ± 1.46
PMID 26388707 · one of two readings recorded this
Rating of perceived exertion, set 2
n = 12
Set 2 | 6.55 ± 1.6a | 6.55 ± 2.02a | 6.23 ± 1.57a | 6.36 ± 1.63a
PMID 26388707 · one of two readings recorded this
Rating of perceived exertion, set 3
n = 12
Set 3 | 7.14 ± 1.10ab | 7.05 ± 1.98ab | 6.73 ± 1.79ab | 7.00 ± 1.84ab
PMID 26388707 · one of two readings recorded this
Rating of perceived exertion, set 4
n = 12
Set 4 | 7.55 ± 1.29abc | 7.59 ± 1.71abc | 7.18 ± 1.94abc | 7.50 ± 1.72abc
PMID 26388707 · one of two readings recorded this
Rating of perceived exertion, set 5
n = 12
Set 5 | 7.91 ± 1.22abc | 7.91 ± 1.51abc | 7.50 ± 1.66abc | 7.73 ± 1.68abc
PMID 26388707 · one of two readings recorded this
Rating of perceived exertion, set 6
n = 12
Set 6 | 8.91 ± 1.22abcde | 8.55 ± 1.37abcde | 8.27 ± 1.49abcde | 8.36 ± 1.36abcde
PMID 26388707 · one of two readings recorded this
Repetition number per set, supplement effect
no effect, n = 12
No supplement effect was observed when analyzing repetition number per set
PMID 26388707 · one of two readings recorded this
Repetition performance across successive sets
decreases, p = 0.0001, n = 12
A significant main effect was observed [P < 0.0001] where repetition performance decreased with each successive set during all treatments
PMID 26388707 · one of two readings recorded this
Repetitions completed, set 1
n = 12
Set 1 | 10.0 ± 0.0 | 10.0 ± 0.0 | 10.0 ± 0.0 | 10.0 ± 0.0
PMID 26388707 · one of two readings recorded this
Repetitions completed, set 2
n = 12
Set 2 | 8.1 ± 2.3a | 9.2 ± 1.1 | 9.3 ± 1.2 | 8.9 ± 1.7
PMID 26388707 · one of two readings recorded this
Repetitions completed, set 3
n = 12
Set 3 | 6.6 ± 2.5ab | 6.7 ± 3.0ab | 7.8 ± 3.2ab | 7.7 ± 2.3ab
PMID 26388707 · one of two readings recorded this
Repetitions completed, set 4
n = 12
Set 4 | 6.0 ± 2.7abc | 5.9 ± 3.1ab | 6.8 ± 3.1ab | 6.5 ± 2.8abc
PMID 26388707 · one of two readings recorded this
Repetitions completed, set 5
n = 12
Set 5 | 4.8 ± 3.0abcd | 5.4 ± 3.4abc | 5.4 ± 2.8abcd | 5.7 ± 3.1abcd
PMID 26388707 · one of two readings recorded this
Repetitions completed, set 6
n = 12
Set 6 | 4.0 ± 2.7abcd | 4.1 ± 2.5abcde | 4.9 ± 3.0abcd | 5.3 ± 3.4abcd
PMID 26388707 · one of two readings recorded this
Repetitions completed, sets 1 - 3
n = 12
Reps sets 1 – 3 | 24.7 ± 4.3 | 25.9 ± 3.6 | 27.1 ± 3.8 | 26.6 ± 3.7
PMID 26388707 · one of two readings recorded this
Repetitions completed, sets 4 - 6
n = 12
Reps sets 4 – 6 | 14.8 ± 8.1 | 15.4 ± 8.7 | 17.1 ± 8.5# | 17.5 ± 9.2#
PMID 26388707 · one of two readings recorded this
Repetitions in sets 4-6, treatment trend
unclear, p = 0.06, n = 12
In addition, a trend (P = 0.06) was observed where most of the differences shown between supplement conditions occurred between sets 4 and 6
PMID 26388707 · one of two readings recorded this
RPE across successive sets, time effect
increases, p = 0.0001, n = 12
A significant time effect was observed between the 1st and 6th set of resistance exercise [P < 0.0001] where RPE values increased with each successive set
PMID 26388707 · one of two readings recorded this
RPE correlated with repetitions completed per set
decreases, p = 0.001, n = 12
RPE obtained during each set was significantly [P < 0.001] negatively correlated with repetitions completed (r = −0.48 to −0.67)
PMID 26388707 · one of two readings recorded this
Total repetitions (6 sets)
increases, n = 12
Total reps | 39.5 ± 12.1 | 41.3 ± 11.9 | 44.2 ± 11.7* | 44.1 ± 12.4*
PMID 26388707 · one of two readings recorded this
total repetitions and volume load over 6 sets of back squat at 80% 1RM (up to 10 reps per set, 2 min rest); also mean power, peak power, RPE (CR10), blood lactate and body mass across conditions
increases
Not recorded as a finding: a node exists but the paper states a different instrument or population
Supplements SCF and S produced significantly greater numbers of repetitions performed than CT and P.
PMID 26388707 · one of two readings recorded this
total repetitions and volume load over 6 sets of back squats at 80% of 1RM; also mean power and velocity (Tendo unit), RPE (CR10) and blood lactate
increases
Not recorded as a finding: this platform holds no node for the endpoint
Supplements SCF and S produced significantly greater numbers of repetitions performed than CT and P.
PMID 26388707 · one of two readings recorded this
Total repetitions, percent difference
increases, n = 12
SCF and S produced ~11.0 ± 8.0 % greater repetition numbers than the CT condition
PMID 26388707 · one of two readings recorded this
Total repetitions, percent difference
increases, n = 12
and ~6.0 ± 7.0 % greater repetition numbers than the P treatment
PMID 26388707 · one of two readings recorded this
Total repetitions, treatment main effect
increases, p = 0.05, n = 12
However, significant differences were observed [P = 0.05] between treatments when total repetitions were analyzed
PMID 26388707 · one of two readings recorded this
Volume load per protocol, treatment main effect
increases, p = 0.03, n = 12
A significant difference was observed [P = 0.03] between treatments
PMID 26388707 · one of two readings recorded this
Volume load per protocol
increases, n = 12
Supplements SCF (4,609.1 ± 1,175.2 kg) and S (4,623.0 ± 1,117.5 kg) produced a significantly greater volume load per protocol than CT (4,128.0 ± 1,258.1 kg) and P (4,321.6 ± 1,136 kg)
PMID 26388707 · one of two readings recorded this
Carbohydrate oxidation rate at low-to-moderate exercise intensities
decreases, n = 18
The acute ingestion of p-synephrine increased the fat oxidation rate while it reduced the carbohydrate oxidation rate when exercising at low-to-moderate exercise intensities
PMID 27038225 · one of two readings recorded this
carbohydrate oxidation rate during incremental cycling, indirect calorimetry
decreases, n = 18
Not recorded as a finding: no carbohydrate oxidation outcome node
The acute ingestion of p-synephrine increased the fat oxidation rate while it reduced the carbohydrate oxidation rate when exercising at low-to-moderate exercise intensities.
PMID 27038225 · one of two readings recorded this
Energy consumption at rest
no effect, p = 0.69, n = 18
did not change energy consumption (1.6 ± 0.3 vs. 1.6 ± 0.3 kcal min(-1) ; P = 0.69)
PMID 27038225 · one of two readings recorded this
Energy expenditure during incremental exercise
no effect, n = 18
the intake of p-synephrine moved the fat oxidation-exercise intensity curve upwards during the incremental exercise (P < 0.05) without affecting energy expenditure
PMID 27038225 · one of two readings recorded this
Exercise intensity at which maximal fat oxidation was achieved
no effect, p = 0.51, n = 18
it did not affect the intensity at which maximal fat oxidation was achieved (55.8 ± 7.7 vs. 56.7 ± 8.2% VO2peak ; P = 0.51)
PMID 27038225 · one of two readings recorded this
fat oxidation during incremental exercise, expressed as the fat oxidation-exercise intensity curve
increases, curve moved upwards, P < 0.05
Not recorded as a finding: fat-oxidation-rate needs a rate at a stated intensity or a bout total; the finding is a curve shift across intensities with no per-intensity rate or total in the sentence
However, the intake of p-synephrine moved the fat oxidation-exercise intensity curve upwards during the incremental exercise (P < 0.05) without affecting energy expenditure.
PMID 27038225 · one of two readings recorded this
Fat oxidation-exercise intensity curve during incremental exercise
increases, p = 0.05, n = 18
the intake of p-synephrine moved the fat oxidation-exercise intensity curve upwards during the incremental exercise (P < 0.05) without affecting energy expenditure
PMID 27038225 · one of two readings recorded this
Fat oxidation rate at low-to-moderate exercise intensities
increases, n = 18
The acute ingestion of p-synephrine increased the fat oxidation rate while it reduced the carbohydrate oxidation rate when exercising at low-to-moderate exercise intensities
PMID 27038225 · one of two readings recorded this
Fat oxidation rate at rest
no effect, p = 0.15, n = 18
or fat oxidation rate at rest (0.08 ± 0.02 vs. 0.10 ± 0.04 g min(-1) ; P = 0.15)
PMID 27038225 · one of two readings recorded this
maximal fat oxidation rate during cycle ergometer ramp exercise, indirect calorimetry
increases, 0.29 vs 0.40 g/min, p = 0.01, n = 18
Not recorded as a finding: this platform holds no node for the endpoint
Moreover, p-synephrine increased maximal fat oxidation rate (0.29 ± 0.15 vs. 0.40 ± 0.18 g min(-1) ; P = 0.01) during exercise although it did not affect the intensity at which maximal fat oxidation was achieved (55.8 ± 7.7 vs. 56.7 ± 8.2% VO2peak ; P = 0.51).
PMID 27038225 · one of two readings recorded this
Maximal fat oxidation rate during exercise
increases, p = 0.01, n = 18
Moreover, p-synephrine increased maximal fat oxidation rate (0.29 ± 0.15 vs. 0.40 ± 0.18 g min(-1) ; P = 0.01) during exercise
PMID 27038225 · one of two readings recorded this
maximal fat oxidation rate (g/min) during a cycle ergometer ramp test, indirect calorimetry; fat oxidation and energy expenditure at rest
increases, 0.29 vs 0.40 g/min, P = 0.01, p = 0.01, n = 18
Not recorded as a finding: this platform holds no node for the endpoint
Moreover, p-synephrine increased maximal fat oxidation rate (0.29 ± 0.15 vs. 0.40 ± 0.18 g min(-1) ; P = 0.01) during exercise although it did not affect the intensity at which maximal fat oxidation was achieved (55.8 ± 7.7 vs. 56.7 ± 8.2% VO2peak ; P = 0.51).
PMID 27038225 · one of two readings recorded this
resting energy consumption, indirect calorimetry, kcal/min
no effect, 1.6 ± 0.3 vs. 1.6 ± 0.3 kcal/min, p = 0.69, n = 18
Not recorded as a finding: resting-energy-expenditure node requires an overnight fast and no prior exercise, and the abstract states neither; the sentence's 'at rest' also attaches grammatically to fat oxidation
In comparison with the placebo, the ingestion of p-synephrine did not change energy consumption (1.6 ± 0.3 vs. 1.6 ± 0.3 kcal min(-1) ; P = 0.69) or fat oxidation rate at rest (0.08 ± 0.02 vs. 0.10 ± 0.04 g min(-1) ; P = 0.15).
PMID 27038225 · one of two readings recorded this
resting energy expenditure ('energy consumption'), indirect calorimetry, kcal/min
no effect, 1.6 vs 1.6 kcal/min, p = 0.69
Not recorded as a finding: resting-energy-expenditure requires lying at rest after an overnight fast without prior exercise, converted to per-day; the abstract states none of those conditions, so the node's measurement cannot be confirmed
In comparison with the placebo, the ingestion of p-synephrine did not change energy consumption (1.6 ± 0.3 vs. 1.6 ± 0.3 kcal min(-1) ; P = 0.69) or fat oxidation rate at rest (0.08 ± 0.02 vs. 0.10 ± 0.04 g min(-1) ; P = 0.15).
PMID 27038225 · one of two readings recorded this
carbohydrate oxidation during 1 h of cycling
decreases, p = 0.01, n = 14
99.5 ± 30.4 vs. 85.0 ± 28.4 g, P < 0.01
PMID 31691018 · one of two readings recorded this
carbohydrate oxidation summed over 1 h of cycling at Fatmax, indirect calorimetry
decreases, 99.5 ± 30.4 vs. 85.0 ± 28.4 g, n = 14
Not recorded as a finding: no carbohydrate oxidation outcome node
However, p-synephrine increased whole-body fat oxidation (33.6 ± 10.4 vs. 37.3 ± 9.8 g, P < 0.01) while also reducing carbohydrate oxidation (99.5 ± 30.4 vs. 85.0 ± 28.4 g, P < 0.01).
PMID 31691018 · one of two readings recorded this
energy expenditure during 1 h of cycling at Fatmax, indirect calorimetry, kcal
no effect, 698 ± 129 vs. 686 ± 123 kcal, p = 0.08, n = 14
Not recorded as a finding: exercising energy expenditure; resting-energy-expenditure node requires a rest measurement after an overnight fast
In comparison to the placebo, energy expenditure during 1 h of cycling remained unchanged with p-synephrine (698 ± 129 vs. 686 ± 123 kcal, P = 0.08).
PMID 31691018 · both readings recorded this
energy expenditure during 1 h of cycling
no effect, p = 0.08, n = 14
698 ± 129 vs. 686 ± 123 kcal, P = 0.08
PMID 31691018 · one of two readings recorded this
whole-body fat oxidation and carbohydrate oxidation over 1 h of cycling at Fatmax, indirect calorimetry
increases
Not recorded as a finding: this platform holds no node for the endpoint
However, p-synephrine increased whole-body fat oxidation (33.6 ± 10.4 vs. 37.3 ± 9.8 g, P < 0.01) while also reducing carbohydrate oxidation (99.5 ± 30.4 vs. 85.0 ± 28.4 g, P < 0.01).
PMID 31691018 · one of two readings recorded this
whole-body fat oxidation during 1 h of cycling
increases, p = 0.01, n = 14
33.6 ± 10.4 vs. 37.3 ± 9.8 g, P < 0.01
PMID 31691018 · one of two readings recorded this
whole-body fat oxidation (g) over 1 h of cycling at Fatmax, indirect calorimetry; also carbohydrate oxidation and energy expenditure
increases, 33.6 vs 37.3 g, P < 0.01, n = 14
Not recorded as a finding: this platform holds no node for the endpoint
However, p-synephrine increased whole-body fat oxidation (33.6 ± 10.4 vs. 37.3 ± 9.8 g, P < 0.01) while also reducing carbohydrate oxidation (99.5 ± 30.4 vs. 85.0 ± 28.4 g, P < 0.01).
PMID 31691018 · one of two readings recorded this
Anthropometric variables
no effect
Statistically significant changes in anthropometric variables, scores of the physical health, mental health, and total score of the SF-12 questionnaire were not found in the study groups
PMID 32438719 · one of two readings recorded this
Blood cell count, liver enzymes, blood urea nitrogen and serum creatinine (safety)
no effect
Neither adverse events nor changes in cell blood count, liver enzymes, and serum levels of blood urea nitrogen and creatinine were observed
PMID 32438719 · one of two readings recorded this
Diastolic blood pressure
decreases, p = 0.045
Between-group differences were significant for diastolic blood pressure (p = 0.045)
PMID 32438719 · one of two readings recorded this
Diastolic blood pressure
decreases, n = 51
Both systolic and diastolic blood pressure decreased significantly in the active product group, whereas changes were not significant among participants treated with placebo
PMID 32438719 · one of two readings recorded this
Diastolic blood pressure
no effect, n = 45
Both systolic and diastolic blood pressure decreased significantly in the active product group, whereas changes were not significant among participants treated with placebo
PMID 32438719 · one of two readings recorded this
Flow-mediated vasodilation (FMD)
increases, p = 0.039
Between-group differences in FMD were statistically significant (p = 0.039)
PMID 32438719 · one of two readings recorded this
Flow-mediated vasodilation (FMD)
increases, p = 0.001, n = 51
The comparison of baseline (6.73 ± 5.27%) and final values (9.77 ± 5.56%) showed statistically significant differences (p < 0.001) in the active product group, whereas differences were not significant in the placebo group
PMID 32438719 · one of two readings recorded this
Flow-mediated vasodilation (FMD)
no effect, n = 45
The comparison of baseline (6.73 ± 5.27%) and final values (9.77 ± 5.56%) showed statistically significant differences (p < 0.001) in the active product group, whereas differences were not significant in the placebo group
PMID 32438719 · one of two readings recorded this
Interleukin-6 (IL-6)
decreases, p = 0.001
Between-group differences in serum levels of IL-6 during the study were statistically significant (p < 0.001)
PMID 32438719 · one of two readings recorded this
Interleukin-6 (IL-6)
decreases, p = 0.001, n = 51
serum levels of IL-6 decreased from 1.49 ± 0.96 pg/mL at baseline to 0.91 ± 0.56 pg/mL after eight weeks of treatment with the active product (p < 0.001)
PMID 32438719 · one of two readings recorded this
Interleukin-6 (IL-6)
no effect, n = 45
whereas changes in the placebo group were not significant
PMID 32438719 · one of two readings recorded this
LDL-C
unclear
with statistically significant differences for within-group comparisons in subjects assigned to the active product group, as well as between group-differences versus placebo
PMID 32438719 · one of two readings recorded this
LDL-C
unclear, n = 51
there was a significant improvement in serum levels of total cholesterol, LDL-C, and oxidized-LDL (ox-LDL), with statistically significant differences for within-group comparisons in subjects assigned to the active product group
PMID 32438719 · one of two readings recorded this
Level of physical activity
no effect
Significant changes in the level of physical activity were not recorded
PMID 32438719 · one of two readings recorded this
Oxidized LDL
unclear
with statistically significant differences for within-group comparisons in subjects assigned to the active product group, as well as between group-differences versus placebo
PMID 32438719 · one of two readings recorded this
Oxidized LDL
unclear, n = 51
there was a significant improvement in serum levels of total cholesterol, LDL-C, and oxidized-LDL (ox-LDL), with statistically significant differences for within-group comparisons in subjects assigned to the active product group
PMID 32438719 · one of two readings recorded this
Protein carbonyl
decreases, p = 0.012
Between-group comparisons of these variables showed statistically significant differences (p = 0.003 and p = 0.012, respectively)
PMID 32438719 · one of two readings recorded this
Protein carbonyl
decreases, n = 51
protein carbonyl decreased significantly in the active product treatment group only
PMID 32438719 · one of two readings recorded this
Reduced/oxidized glutathione ratio (GSH/GSSH)
increases, p = 0.003
Between-group comparisons of these variables showed statistically significant differences (p = 0.003 and p = 0.012, respectively)
PMID 32438719 · one of two readings recorded this
Reduced/oxidized glutathione ratio (GSH/GSSH)
increases, n = 51
the GHS/GSSH ratio increased significantly in the active product treatment product only
PMID 32438719 · one of two readings recorded this
SF-12 physical health, mental health and total scores
no effect
Statistically significant changes in anthropometric variables, scores of the physical health, mental health, and total score of the SF-12 questionnaire were not found in the study groups
PMID 32438719 · one of two readings recorded this
Systolic blood pressure
decreases, n = 51
Both systolic and diastolic blood pressure decreased significantly in the active product group, whereas changes were not significant among participants treated with placebo
PMID 32438719 · one of two readings recorded this
Systolic blood pressure
no effect, n = 45
Both systolic and diastolic blood pressure decreased significantly in the active product group, whereas changes were not significant among participants treated with placebo
PMID 32438719 · one of two readings recorded this
Total cholesterol
unclear
with statistically significant differences for within-group comparisons in subjects assigned to the active product group, as well as between group-differences versus placebo
PMID 32438719 · one of two readings recorded this
Total cholesterol
unclear, n = 51
there was a significant improvement in serum levels of total cholesterol, LDL-C, and oxidized-LDL (ox-LDL), with statistically significant differences for within-group comparisons in subjects assigned to the active product group
PMID 32438719 · one of two readings recorded this
von Willebrand factor
no effect
No significant differences were found in levels of the von Willebrand factor for any other group of the study
PMID 32438719 · one of two readings recorded this
diastolic blood pressure
53.30 ± 10.13, 134.82 ± 11.75 mm Hg, 84.49 ± 6.99 mm Hg, 17.87 ± 1.73 times/min, and 76.48 ± 12.55 beats/min at baseline
PMID 32572778 · one of two readings recorded this
diastolic blood pressure
decreases, p = 0.05
significantly decreased to 42.37 ± 10.15, 124.49 ± 10.48 mm Hg, 79.23 ± 6.62 mm Hg, 14.54 ± 1.43 times/min, and 70.03 ± 13.66 beats/min respectively 20 min after intervention (all P<0.05)
PMID 32572778 · one of two readings recorded this
pulse rate
53.30 ± 10.13, 134.82 ± 11.75 mm Hg, 84.49 ± 6.99 mm Hg, 17.87 ± 1.73 times/min, and 76.48 ± 12.55 beats/min at baseline
PMID 32572778 · one of two readings recorded this
pulse rate
decreases, p = 0.05
significantly decreased to 42.37 ± 10.15, 124.49 ± 10.48 mm Hg, 79.23 ± 6.62 mm Hg, 14.54 ± 1.43 times/min, and 70.03 ± 13.66 beats/min respectively 20 min after intervention (all P<0.05)
PMID 32572778 · one of two readings recorded this
respiratory rate
53.30 ± 10.13, 134.82 ± 11.75 mm Hg, 84.49 ± 6.99 mm Hg, 17.87 ± 1.73 times/min, and 76.48 ± 12.55 beats/min at baseline
PMID 32572778 · one of two readings recorded this
respiratory rate
decreases, p = 0.05
significantly decreased to 42.37 ± 10.15, 124.49 ± 10.48 mm Hg, 79.23 ± 6.62 mm Hg, 14.54 ± 1.43 times/min, and 70.03 ± 13.66 beats/min respectively 20 min after intervention (all P<0.05)
PMID 32572778 · one of two readings recorded this
STAI score and vital signs
no effect, p = 0.05
in the control group, neither anxiety scores nor vital signs changed significantly (P>0.05)
PMID 32572778 · one of two readings recorded this
STAI score
53.30 ± 10.13, 134.82 ± 11.75 mm Hg, 84.49 ± 6.99 mm Hg, 17.87 ± 1.73 times/min, and 76.48 ± 12.55 beats/min at baseline
PMID 32572778 · one of two readings recorded this
STAI score
decreases, p = 0.05
significantly decreased to 42.37 ± 10.15, 124.49 ± 10.48 mm Hg, 79.23 ± 6.62 mm Hg, 14.54 ± 1.43 times/min, and 70.03 ± 13.66 beats/min respectively 20 min after intervention (all P<0.05)
PMID 32572778 · one of two readings recorded this
systolic blood pressure
53.30 ± 10.13, 134.82 ± 11.75 mm Hg, 84.49 ± 6.99 mm Hg, 17.87 ± 1.73 times/min, and 76.48 ± 12.55 beats/min at baseline
PMID 32572778 · one of two readings recorded this
systolic blood pressure
decreases, p = 0.05
significantly decreased to 42.37 ± 10.15, 124.49 ± 10.48 mm Hg, 79.23 ± 6.62 mm Hg, 14.54 ± 1.43 times/min, and 70.03 ± 13.66 beats/min respectively 20 min after intervention (all P<0.05)
PMID 32572778 · one of two readings recorded this
energy expenditure during exercise
no effect, p = 0.4
The ingestion of p-synephrine had no significant effects on energy expenditure (F = 0.71, P = 0.40)
PMID 32859142 · one of two readings recorded this
energy expenditure during incremental exercise, stoichiometric equations
no effect, F = 0.71, p = 0.4
Not recorded as a finding: no node: resting-energy-expenditure requires measurement at rest, and this is exercising expenditure
The ingestion of p-synephrine had no significant effects on energy expenditure (F = 0.71, P = 0.40) or heart rate (F = 0.66, P = 0.43) during exercise.
PMID 32859142 · one of two readings recorded this
exercise intensity of maximal fat oxidation (Fatmax)
no effect, p = 0.52
Fatmax = 49; 48-53 vs 50; 47-51% Wmax, P = 0.52
PMID 32859142 · one of two readings recorded this
fat oxidation rate and maximal fat oxidation (MFO, Fatmax) during incremental cycle ergometer test, breath-by-breath stoichiometric estimate; energy expenditure and heart rate during exercise
no effect, maximal fat oxidation rate 0.91 vs 1.01 g/min, 95% CI 0.79-1.03 vs 0.91-1.11, p = 0.06
Not recorded as a finding: this platform holds no node for the endpoint
The ingestion of p-synephrine did not modify the maximal rate of fat oxidation during the ramp test (mean value; 95%CI = 0.91; 0.79-1.03 vs 1.01; 0.91-1.11 g/min, respectively, P = 0.06) nor the exercise intensity at which maximal fat oxidation was achieved (i.e. Fatmax = 49; 48-53 vs 50; 47-51% Wmax, P = 0.52).
PMID 32859142 · one of two readings recorded this
heart rate during exercise
no effect, p = 0.43
heart rate (F = 0.66, P = 0.43) during exercise
PMID 32859142 · one of two readings recorded this
maximal rate of fat oxidation during ramp test
no effect, p = 0.06
mean value; 95%CI = 0.91; 0.79-1.03 vs 1.01; 0.91-1.11 g/min, respectively, P = 0.06
PMID 32859142 · one of two readings recorded this
maximal rate of fat oxidation (g/min) and Fatmax during an incremental maximal cycle ergometer test, breath-by-breath gas exchange
no effect, maximal fat oxidation 0.91 vs 1.01 g/min, P = 0.06; Fatmax 49 vs 50% Wmax, P = 0.52, p = 0.06, n = 15
Not recorded as a finding: this platform holds no node for the endpoint
The ingestion of p-synephrine did not modify the maximal rate of fat oxidation during the ramp test (mean value; 95%CI = 0.91; 0.79-1.03 vs 1.01; 0.91-1.11 g/min, respectively, P = 0.06) nor the exercise intensity at which maximal fat oxidation was achieved (i.e. Fatmax = 49; 48-53 vs 50; 47-51% Wmax, P = 0.52).
PMID 32859142 · one of two readings recorded this
rate of fat oxidation at the loads tested
increases
the rate of fat oxidation was higher with p-synephrine in the following loads
PMID 32859142 · one of two readings recorded this
rate of fat oxidation, main effect
increases, p = 0.04
there was a main effect of p-synephrine to increase the rate of fat oxidation over the placebo (F = 5.1, P = 0.04)
PMID 32859142 · one of two readings recorded this
quality of life
increases
There was a significant difference between the mean score of quality of life in the Lavender essential oil group and Citrus Aurantium essential oil group with the control group after intervention
PMID 32889038 · one of two readings recorded this
quality of life
increases
There was a significant difference between the mean score of quality of life in the Lavender essential oil group and Citrus Aurantium essential oil group with the control group after intervention
PMID 32889038 · one of two readings recorded this
quality of life
no effect
However, there was no significant difference between the mean score of quality of life in the Lavender essential oil group and Citrus Aurantium essential oil group after the intervention
PMID 32889038 · one of two readings recorded this
pain score, all groups over the study
decreases, p = 0.001
Pain scores of all groups decreased during the study (P < 0.001)
PMID 33516726 · one of two readings recorded this
pain score, lavender versus placebo
decreases
The mean pain of the lavender group was significantly lower than that of the placebo group at three hours after the intervention
PMID 33516726 · one of two readings recorded this
pain score
decreases
The mean pain score of the C. aurantium group was 45.48 before the intervention and was reduced to 32.34 at three hours after the intervention
PMID 33516726 · one of two readings recorded this
pain score
no effect
The mean pain score of the lavender group was 40.01 before the aromatherapy intervention and fell to 39.40, 30.60 and 23.68 immediately after the intervention, and at hour one and three post-intervention, respectively
PMID 33516726 · one of two readings recorded this
pain score
decreases
The mean pain score of the lavender group was 40.01 before the aromatherapy intervention and fell to 39.40, 30.60 and 23.68 immediately after the intervention, and at hour one and three post-intervention, respectively
PMID 33516726 · one of two readings recorded this
pain score
decreases
The mean pain score of the lavender group was 40.01 before the aromatherapy intervention and fell to 39.40, 30.60 and 23.68 immediately after the intervention, and at hour one and three post-intervention, respectively
PMID 33516726 · one of two readings recorded this
pain score
decreases
The mean pain of the placebo group decreased from 42.80 before the intervention to 35.20 at three hours after the intervention
PMID 33516726 · one of two readings recorded this
anxiety severity (STAI) in women
increases, p = 0.05
In addition, the severity of anxiety in women in the control group increased after placebo intervention (p<0.05)
PMID 33984876 · one of two readings recorded this
relatively severe anxiety in women, spring orange group
decreases
In women, relatively severe anxiety was not observed after the intervention with lavender, but in the spring orange group, only in 6.7% of people, relatively severe anxiety and traits were observed
PMID 33984876 · one of two readings recorded this
Best-corrected visual acuity (BCVA)
no effect, p = 0.502, n = 30
BCVA | 100.77 ± 9.02 | 103.08 ± 6.01 | 0.185 | 103.00 ± 7.83 | 102.33 ± 7.51 | 0.502
PMID 34647961 · one of two readings recorded this
Best-corrected visual acuity (BCVA)
no effect, p = 0.185, n = 26
BCVA | 100.77 ± 9.02 | 103.08 ± 6.01 | 0.185 | 103.00 ± 7.83 | 102.33 ± 7.51 | 0.502
PMID 34647961 · one of two readings recorded this
Cone sensitivity
no effect, p = 0.996, n = 30
Cone sensitivity (%) | 5.86 ± 2.97 | 5.37 ± 3.18 | 0.159 | 4.84 ± 1.88 | 4.84 ± 1.85 | 0.996
PMID 34647961 · one of two readings recorded this
Cone sensitivity
no effect, p = 0.159, n = 26
Cone sensitivity (%) | 5.86 ± 2.97 | 5.37 ± 3.18 | 0.159 | 4.84 ± 1.88 | 4.84 ± 1.85 | 0.996
PMID 34647961 · one of two readings recorded this
Effect of floaters on daily life, mean score
decreases, p = 0.002, n = 30
Mean score | 1.08 ± 0.85 | 1.00 ± 1.06 | 0.678 | 1.37 ± 1.27 | 0.73 ± 0.94 | 0.002 *
PMID 34647961 · one of two readings recorded this
Effect of floaters on daily life, mean score
no effect, p = 0.678, n = 26
Mean score | 1.08 ± 0.85 | 1.00 ± 1.06 | 0.678 | 1.37 ± 1.27 | 0.73 ± 0.94 | 0.002 *
PMID 34647961 · one of two readings recorded this
Letter contrast sensitivity, 1.5 cpd
no effect, p = 0.749, n = 30
1.5 cpd | 1.90 ± 0.18 | 1.93 ± 0.14 | 0.354 | 1.96 ± 0.20 | 1.95 ± 0.19 | 0.749
PMID 34647961 · one of two readings recorded this
Letter contrast sensitivity, 1.5 cpd
no effect, p = 0.354, n = 26
1.5 cpd | 1.90 ± 0.18 | 1.93 ± 0.14 | 0.354 | 1.96 ± 0.20 | 1.95 ± 0.19 | 0.749
PMID 34647961 · one of two readings recorded this
Letter contrast sensitivity, 12 cpd
no effect, p = 0.51, n = 30
12 cpd | 1.27 ± 0.39 | 1.39 ± 0.29 | 0.104 | 1.38 ± 0.36 | 1.42 ± 0.40 | 0.510
PMID 34647961 · one of two readings recorded this
Letter contrast sensitivity, 12 cpd
no effect, p = 0.104, n = 26
12 cpd | 1.27 ± 0.39 | 1.39 ± 0.29 | 0.104 | 1.38 ± 0.36 | 1.42 ± 0.40 | 0.510
PMID 34647961 · one of two readings recorded this
Letter contrast sensitivity, 18.95 cpd
no effect, p = 0.281, n = 30
18.95 cpd | 0.94 ± 0.49 | 1.02 ± 0.38 | 0.276 | 1.07 ± 0.33 | 1.12 ± 0.33 | 0.281
PMID 34647961 · one of two readings recorded this
Letter contrast sensitivity, 18.95 cpd
no effect, p = 0.276, n = 26
18.95 cpd | 0.94 ± 0.49 | 1.02 ± 0.38 | 0.276 | 1.07 ± 0.33 | 1.12 ± 0.33 | 0.281
PMID 34647961 · one of two readings recorded this
Letter contrast sensitivity, 3 cpd
no effect, p = 0.109, n = 30
3 cpd | 1.87 ± 0.18 | 1.89 ± 0.17 | 0.465 | 1.94 ± 0.19 | 1.98 ± 0.22 | 0.109
PMID 34647961 · one of two readings recorded this
Letter contrast sensitivity, 3 cpd
no effect, p = 0.465, n = 26
3 cpd | 1.87 ± 0.18 | 1.89 ± 0.17 | 0.465 | 1.94 ± 0.19 | 1.98 ± 0.22 | 0.109
PMID 34647961 · one of two readings recorded this